UMB Announces Agreement to Acquire Heartland Financial
April 29, 2024 07:30 ET
|
Heartland Financial USA, Inc.
Largest acquisition in UMB history will increase total assets by more than 40% and significantly expand geographic footprint UMB investment community call today, Monday, April 29, at 7:30 a.m. (CT) /...
Dragonfly Energy to Report First Quarter 2024 Financial and Operational Results on May 14, 2024
April 29, 2024 07:30 ET
|
Dragonfly Energy Holdings Corp.
Dragonfly Energy to release Q1 2024 financial and operational results on May 14, 2024, after market close, followed by an earnings call at 5pm ET.
Alterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich’s Ataxia
April 29, 2024 07:25 ET
|
ALTERITY THERAPEUTICS LIMITED
– New Evidence Indicates ATH434 can Function as an Iron Chaperone to Redistribute Iron – MELBOURNE, Australia and SAN FRANCISCO, April 29, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX:...
EYLEA® HD (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Sustained and Clinically Meaningful Outcomes in Serious Retinal Diseases
April 29, 2024 07:00 ET
|
Regeneron Pharmaceuticals, Inc.
TARRYTOWN, N.Y., April 29, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the presentation of positive long-term results and subgroup analyses from the...
POET Announces CAD$10 Million Non-brokered Financing
April 29, 2024 07:00 ET
|
POET Technologies Inc.
NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, April 29, 2024 (GLOBE NEWSWIRE) -- POET Technologies Inc. (“POET” or the “Company”) (TSX Venture:...
Aquestive Therapeutics Receives U.S. FDA Approval and Market Access for Libervant™ (diazepam) Buccal Film in Pediatric Patients Ages 2 to 5 and Provides Update on Anaphylm™ (epinephrine) Sublingual Film
April 29, 2024 07:00 ET
|
Aquestive Therapeutics, Inc.
Libervant is the first and only FDA approved orally administered rescue product for the treatment of seizure clusters in patients ages 2 to 5Announces immediate availability of Libervant 5mg, 7.5mg,...
Prime Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)
April 29, 2024 07:00 ET
|
Prime Medicine, Inc.
Prime Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)
Atea Announces Presentation of Data Highlighting Favorable Safety Profile of Bemnifosbuvir at ESCMID Global 2024
April 29, 2024 07:00 ET
|
Atea Pharmaceuticals, Inc.
BOSTON, April 29, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral...
ECARX to Report First Quarter 2024 Financial Results on May 20, 2024
April 29, 2024 07:00 ET
|
ECARX LIMITED
SHANGHAI, China, April 29, 2024 (GLOBE NEWSWIRE) -- ECARX Holdings, Inc. (Nasdaq: ECX) ("ECARX"), a global mobility tech provider, today announced that it will report its financial results for the...
Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Requirement
April 29, 2024 07:00 ET
|
Allarity Therapeutics, Inc.
Boston (April 29, 2024) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments,...